Compare · ELV vs MTAC
ELV vs MTAC
Side-by-side comparison of Elevance Health Inc. (ELV) and MedTech Acquisition Corporation (MTAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and MTAC operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.24B, about 292.3x MTAC ($308.8M).
- ELV has hit the wire 3 times in the past 4 weeks while MTAC has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 0 for MTAC).
- Company
- Elevance Health Inc.
- MedTech Acquisition Corporation
- Price
- $415.68+1.52%
- $11.67+15.43%
- Market cap
- $90.24B
- $308.8M
- 1M return
- +10.97%
- -
- 1Y return
- +6.68%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 3
- 0
- Recent ratings
- 23
- 0
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
MedTech Acquisition Corporation
MedTech Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest MTAC
- Szela Mary T was granted 84,899 shares, increasing direct ownership by 30% to 364,862 units (SEC Form 4)
- Marshak Richard was granted 14,752 shares, increasing direct ownership by 118% to 27,251 units (SEC Form 4)
- Cox Bryan F. was granted 14,752 shares, increasing direct ownership by 21% to 86,696 units (SEC Form 4)
- Stevens Jennifer was granted 14,752 shares, increasing direct ownership by 82% to 32,783 units (SEC Form 4)
- Devlin Jodi was granted 17,500 shares (SEC Form 4)
- Murphy Sean was granted 34,144 shares, increasing direct ownership by 205% to 50,788 units (SEC Form 4)
- Katz Steven C was granted 34,144 shares, increasing direct ownership by 99% to 68,587 units (SEC Form 4)
- SEC Form 4 filed by Murphy Sean
- SEC Form 4 filed by Marshak Richard
- SEC Form 424B3 filed by MedTech Acquisition Corporation